Skip to content
DNDi Logo
  • DNDi INTERNATIONAL
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT DNDi
    • ABOUT DNDi NORTH AMERICA
    • OUR TEAM
    • BOARD OF DIRECTORS
    • OUR PUBLICATIONS
    • FINANCIALS
    • JOBS
    • Close
  • DISEASES & PROJECTS
  • ADVOCACY
  • MEDIA CENTER
  • DONATE
  • CONTACT
    • Close
  • Home

Media Center

RSS SCIENTIFIC ARTICLES

  • Hard to study, hard to treat: putting children at the centre of antibiotic research and development
  • Exploring global and country-level barriers to an effective supply of leishmaniasis medicines and diagnostics in eastern Africa: a qualitative study
  • Synergic effect of allopurinol in combination with nitroheterocyclic compounds against Trypanosoma cruzi

RSS PRESS RELEASES

  • Following 110 years of neglect, an official day for Chagas disease is declared
  • DNDi and Atomwise collaborate to advance drug development using AI for neglected diseases
  • Chagas disease: the time is now to end 110 years of neglect

RSS NEWS

  • DNDi receives 1 billion yen from Takeda to improve access to treatment for neglected patients
  • Study for a child-friendly HIV treatment begins in Uganda
  • ‘We had to do something’ – Beginnings of the Access Campaign

RSS IN THE MEDIA

  • DDNews: “Duo ‘AIMS’ at AI-powered discovery efforts”
  • Un Seul Monde – SDC Magazine: “Partnerships that save lives”
  • Health Policy Watch: “Negotiators agree on game-changing WHA resolution for medicine price disclosure”

RSS EVENTS

  • DNDi and founders’ symposium
  • 2nd LEAP Scientific Conference
  • ECTMIH 2019

RSS Scientific Articles

  • Hard to study, hard to treat: putting children at the centre of antibiotic research and development
  • Exploring global and country-level barriers to an effective supply of leishmaniasis medicines and diagnostics in eastern Africa: a qualitative study
  • Synergic effect of allopurinol in combination with nitroheterocyclic compounds against Trypanosoma cruzi
  • Drug discovery for Chagas disease: Impact of different host cell lines on assay performance and hit compound selection

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

Subscribe

Sign up for the E-news newsletter! By subscribing, you agree that all info submitted will be processed according to our Privacy Policy. You can unsubscribe any time.

I want to receive

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website

Donate

Support research for neglected disease treatments by making a gift

Authorize.net Seal

Charity Status

GuideStar Gold Participantnewyork-ac-seal-vertical-black-web

Social Mission Ratio

Social Mission Ration 2017

  • PRIVACY POLICY
  • TERMS OF USE
  • ACCEPTABLE USE POLICY
  • COOKIE POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser. Read Cookie Policy. Close